- Home
- AARD vs TNYA Comparison
AARD vs TNYA Comparison
Compare AARD & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AARD | TNYA |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | 97 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.9M | 234.8M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AARD | TNYA |
|---|---|---|
| Price | $13.38 | $1.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $30.63 | $8.60 |
| AVG Volume (30 Days) | 178.7K | ★ 2.4M |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.88 | $0.36 |
| 52 Week High | $19.58 | $4.01 |
Technical Indicators
Market Signals| Indicator | AARD | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 66.65 | 52.56 |
| Support Level | $9.18 | $1.21 |
| Resistance Level | $10.44 | $1.42 |
| Average True Range (ATR) | 0.91 | 0.10 |
| MACD | 0.46 | 0.02 |
| Stochastic Oscillator | 94.75 | 96.36 |
Price Performance
Historical ComparisonAbout AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.